Does Rinvoq Work for Ulcerative Colitis Flares?
Rinvoq (upadacitinib), a JAK inhibitor, is FDA-approved for moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to other therapies, including flares.[1] Clinical trials show it induces clinical remission in 26-33% of patients at week 8 and 36-46% at week 52, compared to 4-5% on placebo.[2][3]
How Rinvoq Performs in Key Trials for Flares
In the U-ACHIEVE induction trial (phase 3), 33% of patients on 45 mg daily Rinvoq achieved clinical remission (modified Mayo score ≤2 with no subscore >1) at week 8, versus 4% on placebo. Endoscopic improvement occurred in 26% versus 4%.[2] The U-ACCOMPLISH trial showed similar results: 26% remission rate.[3] Maintenance data from U-ACHIEVE (30 mg dose) hit 46% remission at week 52.[4] These outcomes held across biologic-failed patients, directly addressing flare control.
Rinvoq vs. Other UC Treatments During Flares
Rinvoq outperforms placebo and matches or exceeds TNF inhibitors like infliximab (16-21% remission at week 8 in similar trials).[5] Compared to vedolizumab (anti-integrin), Rinvoq showed faster onset (week 8 remission: 33% vs. 14-24%).[6] Unlike steroids, which manage acute flares short-term but risk dependency, Rinvoq offers sustained remission without tapering.[1]
Common Side Effects During Flare Treatment
Upper respiratory infections (18%), anemia (7%), and herpes zoster (3-4%) top the list in UC trials.[2][3] Serious infections occurred in 3%, with boxed warnings for infections, malignancy, thrombosis, and GI tears.[1] No increased cardiovascular risk in UC data, unlike rheumatoid arthritis studies.
Who Responds Best and When to Expect Results
Biologic-naive patients hit 42% remission at week 8 on 45 mg; biologic-failed drop to 27%.[2] Endoscopic response starts by week 2 in responders. Non-responders by week 8 rarely remit later.[4] Dosage: 45 mg induction (8 weeks), then 15-30 mg maintenance.[1]
Long-Term Data and Patent Timeline
Week 52 maintenance remission: 42% (15 mg) to 52% (30 mg).[4] Patent expiry for Rinvoq in UC is around 2033, per DrugPatentWatch.com (check specific claims).[7] No biosimilars yet due to ongoing exclusivity.
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s009lbl.pdf
[2] Sandborn et al., Lancet 2022 (U-ACHIEVE): https://pubmed.ncbi.nlm.nih.gov/35065063/
[3] Danese et al., Gastroenterology 2022 (U-ACCOMPLISH): https://pubmed.ncbi.nlm.nih.gov/35065062/
[4] Vermeire et al., Lancet 2022 (maintenance): https://pubmed.ncbi.nlm.nih.gov/35065064/
[5] ACT-1 trial (infliximab): https://pubmed.ncbi.nlm.nih.gov/17087934/
[6] Sands et al., NEJM 2017 (vedolizumab): https://pubmed.ncbi.nlm.nih.gov/28646835/
[7] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/RINVOQ